SAB Biotherapeutics Files 8-K on Officer/Director Changes
Ticker: SABSW · Form: 8-K · Filed: Sep 30, 2025 · CIK: 1833214
| Field | Detail |
|---|---|
| Company | Sab Biotherapeutics, Inc. (SABSW) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-changes, director-changes, compensation
TL;DR
SAB Biotherapeutics 8-K: Leadership changes and compensation details filed Sept 30, 2025.
AI Summary
SAB Biotherapeutics, Inc. filed an 8-K on September 30, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and executive compensation, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensation details, can signal internal shifts that may affect company strategy and performance.
Key Players & Entities
- SAB Biotherapeutics, Inc. (company) — Registrant
- September 30, 2025 (date) — Date of earliest event reported
- Big Cypress Acquisition Corp. (company) — Former company name
FAQ
What specific officer or director positions were affected by the changes reported in this 8-K?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but does not specify individual names or positions within the provided text.
Are there any details regarding new compensatory arrangements for officers mentioned in the filing?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not included in the provided excerpt.
When was SAB Biotherapeutics, Inc. formerly known as Big Cypress Acquisition Corp.?
The date of the name change from Big Cypress Acquisition Corp. to SAB Biotherapeutics, Inc. was November 20, 2020.
What is the SIC code for SAB Biotherapeutics, Inc.?
The Standard Industrial Classification (SIC) code for SAB Biotherapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is the fiscal year end for SAB Biotherapeutics, Inc.?
The fiscal year end for SAB Biotherapeutics, Inc. is December 31 (1231).
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-09-30 16:35:29
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq
Filing Documents
- sabs-20250930.htm (8-K) — 45KB
- 0001193125-25-225119.txt ( ) — 183KB
- sabs-20250930.xsd (EX-101.SCH) — 46KB
- sabs-20250930_htm.xml (XML) — 6KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: September 30, 2025 By: /s/ Samuel J. Reich Samuel J. Reich Chief Executive Officer